Brace Pharma Capital is the strategic investment subsidiary of EMS S/A, a Brazilian pharmaceutical company. They invest in therapies for diseases with a high degree of unmet medical need and insufficient treatment options. Brace Pharma Capital invest 80% of their portfolio in clinical phase projects, and the remaining 20% in pre-clinical projects.
Part of their investment criteria, Brace Pharma Capital looks for therapies with what they deem a high probability of technical and regulatory success with defined, FDA validated, clinical efficacy endpoints. And they look for clinical stage projects to go to market in three to five years, and pre-clinical to go to market in five to seven years with the potential of over $200 million in revenue.
Brace Pharma Capital has invested in Avidity Biosciences, ReViral, Antiva Biosciences, Prevision BioSciences, AVROBIO, Antiva Biosciences, MiRagen, F2G, Zymeworks and Navitor Pharmaceuticals.
They have exited their investments in Precision BioSciences, Zymeworks, Avrobio, UNUM Therapeutics, and MiRagen.
Timeline
People
Alan Cohen, M.D., FAAP, FCCP, FAAAAI, FACAAI
Medical Advisor
Daniel E. Salazar, Ph.D
Vice President of Clinical & Regulatory
Lina Arslanian
Executive Assistant & Office Manager
Pedro Bordeaux, M.S.
Associate
Samuel Broder, M.D.
Medical Advisor
Todd Brady
Director of Finance & Investments
Vinzenz Ploerer
President and CEO
